Chemotactic cytokines, obesity and type 2 diabetes: In vivo and in vitro evidence for a possible causal correlation?

Proceedings of the Nutrition Society

Volumn 68, Issue 4, 2009, Pages 378-384

  Sell, Henrike ^a   Eckel, Jürgen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Adipose tissue; Chemerin; Chemokine; Insulin resistance; Obesity

Indexed keywords

ADIPOCYTOKINE; CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES;

ADIPOSE TISSUE; CONFERENCE PAPER; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; ANIMAL; IMMUNOLOGY; INSULIN RESISTANCE; MACROPHAGE; METABOLISM; MOUSE; PATHOLOGY; REVIEW; SECRETION;

ADIPOSE TISSUE; ANIMALS; CHEMOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; MICE; OBESITY;

EID: 77949330439     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665109990218     Document Type: Conference Paper

References (76)

1. Dandona P, Aljada A, Chaudhuri A et al. (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454.
2. Despres JP (2006) Is visceral obesity the cause of the metabolic syndrome? Ann Med 38, 52-63.
3. Jones DB & Gill GV (1997) Non-insulin-dependent diabetes mellitus. In Textbook of Diabetes, 2nd ed., pp. 17.1-17.13 [JC Pickup and G Williams, editors]. Oxford: Blackwell Science.
4. Goran MI, Ball GD & Cruz ML (2003) Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 88, 1417-1427.
5. Argiles JM, Lopez-Soriano J, Almendro V et al. (2005) Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev 25, 49-65.
6. Krebs M & Roden M (2005) Molecular mechanisms of lipidinduced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 7, 621-632.
7. Coppack SW (2005) Adipose tissue changes in obesity. Biochem Soc Trans 33, 1049-1052.
8. Rollins BJ (1997) Chemokines. Blood 90, 909-928.
9. Bozaoglu K, Bolton K, McMillan J et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148, 4687-4694.
10. BaggioliniM(1998) Chemokines and leukocyte traffic. Nature 392, 565-568.
11. Christiansen T, Richelsen B & Bruun JM (2005) Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29, 146-150.
12. Kim CS, Park HS, Kawada T et al. (2006) Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30, 1347-1355.
13. Herder C, Baumert J, Thorand B et al. (2006) Chemokines as risk factors for type 2 diabetes: results from the MONICA/ KORA Augsburg study, 1984-2002. Diabetologia 49, 921-929.
14. Malavazos AE, Ermetici F, Coman C et al. (2006) Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 121, 132-134.
15. Huber J, Kiefer FW, Zeyda M et al. (2008) CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 93, 3215-3221.
16. Piemonti L, Calori G, Mercalli A et al. (2003) Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26, 2883-2889.
17. Simeoni E, Hoffmann MM, Winkelmann BR et al. (2004) Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 47, 1574-1580.
18. Troseid M, Lappegard KT, Claudi T et al. (2004) Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J 25, 349-355.
19. Di Gregorio GB, Yao-Borengasser A, Rasouli N et al. (2005) Expression of CD68 and macrophage chemoattractant protein- 1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54, 2305-2313.
20. Schernthaner GH, Kopp HP, Kriwanek S et al. (2006) Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractantprotein- 1 in morbid obesity. Obes Surg 16, 709-715.
21. Bruun JM, Lihn AS, Pedersen SB et al. (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT. J Clin Endocrinol Metab 90, 2282-2289.
22. Cancello R, Henegar C, Viguerie N et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277-2286.
23. Hashimoto I, Wada J, Hida A et al. (2006) Elevated serum monocyte chemoattractant protein-4 and chronic inflammation in overweight subjects. Obesity (Silver Spring) 14, 799-811.
24. Murdolo G, Hammarstedt A, Sandqvist M et al. (2007) Monocyte chemoattractant protein-1 in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin. J Clin Endocrinol Metab 92, 2688-2695.
25. Jiao P, Chen Q, Shah S et al. (2009) Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes 58, 104-115.
26. Herder C, Haastert B, Muller-Scholze S et al. (2005) Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54, Suppl. 2, S11-S17.
27. Vasudevan AR, Wu H, Xydakis AM et al. (2006) Eotaxin and obesity. J Clin Endocrinol Metab 91, 256-261.
28. Bruun JM, Pedersen SB & Richelsen B (2001) Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 86, 1267-1273.
29. Straczkowski M, Dzienis-Straczkowska S, Stepien A et al. (2002) Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87, 4602-4606.
30. Rotter V, Nagaev I & Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777-45784.
31. Herder C, Schneitler S, Rathmann W et al. (2007) Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 92, 4569-4574.
32. Chavey C, Lazennec G, Lagarrigue S et al. (2009) CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 9, 339-349.
33. Wittamer V, Franssen JD, Vulcano M et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198, 977-985.
34. Goralski KB, McCarthy TC, Hanniman EA et al. (2007) Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 282, 28175-28188.
35. Sartipy P & Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100, 7265-7270.
36. Sell H, Dietze-Schroeder D, Kaiser U et al. (2006) Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147, 2458-2467.
37. Gerhardt CC, Romero IA, Cancello R et al. (2001) Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 175, 81-92.
38. Dietze-Schroeder D, Sell H, Uhlig M et al. (2005) Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 54, 2003-2011.
39. Skurk T, Alberti-Huber C, Herder C et al. (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023-1033; Epublication 12 December 2006.
40. Fain JN & Madan AK (2005) Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissue. Int J Obes (Lond) 29, 1299-1307.
41. Fasshauer M, Klein J, Kralisch S et al. (2004) Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 317, 598-604.
42. Kanda H, Tateya S, Tamori Y et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 1494-1505.
43. Inouye KE, Shi H, Howard JK et al. (2007) Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56, 2242-2250.
44. Kamei N, Tobe K, Suzuki R et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281, 26602-26614.
45. Chen A, Mumick S, Zhang C et al. (2005) Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13, 1311-1320.
46. Weisberg SP, Hunter D, Huber R et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116, 115-124.
47. Tamura Y, Sugimoto M, Murayama T et al. (2008) Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 28, 2195-2201.
48. Yang SJ, IglayReger HB, Kadouh HC et al. (2009) Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 52, 972-981.
49. Lihn AS, Pedersen SB & Richelsen B (2005) Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 6, 13-21.
50. Tschritter O, Fritsche A, Thamer C et al. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239-243.
51. Herder C, Hauner H, Haastert B et al. (2006) Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care 29, 1626-1631.
52. Roh SG, Song SH, Choi KC et al. (2007) Chemerin - a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 362, 1013-1018.
53. Zabel BA, Ohyama T, Zuniga L et al. (2006) Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-beta and TLR ligands. Exp Hematol 34, 1106-1114.
54. Takahashi M, Takahashi Y, Takahashi K et al. (2008) Chemerin enhances insulin signaling and potentiates insulinstimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 582, 573-578.
55. Kralisch S, Weise S, Sommer G et al. (2009) Interleukin- 1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 154, 102-106.
56. Wittamer V, Gregoire F, Robberecht P et al. (2004) The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem 279, 9956-9962.
57. Cash JL, Hart R, Russ A et al. (2008) Synthetic chemerinderived peptides suppress inflammation through ChemR23. J Exp Med 205, 767-775.
58. Zabel BA, Nakae S, Zuniga L et al. (2008) Mast cellexpressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med 205, 2207-2220.
59. Zhang Y & Rollins BJ (1995) A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 15, 4851-4855.
60. Proudfoot AE, Power CA, Hoogewerf AJ et al. (1996) Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271, 2599-2603.
61. Weisberg SP, McCann D, Desai M et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808.
62. Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74, 443-477.
63. Zeyda M, Farmer D, Todoric J et al. (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31, 1420-1428.
64. Murano I, Barbatelli G, Parisani V et al. (2008) Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49, 1562-1568.
65. Lumeng CN, Deyoung SM, Bodzin JL et al. (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16-23.
66. Clement K, Viguerie N, Poitou C et al. (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18, 1657-1669.
67. Lumeng CN, Bodzin JL & Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117, 175-184.
68. IS Wood, F Pérez de Heredia, B Wang et al. (2009) Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 68 (In the Press).
69. Ye J, Gao Z, Yin J et al. (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293, E1118-E1128.
70. Hosogai N, Fukuhara A, Oshima K et al. (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911.
71. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
72. Wang B, Wood IS & Trayhurn P (2007) Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 455, 479-492.
73. Skurk T, Mack I, Kempf K et al. (2009) Expression and secretion of RANTES (CCL5) in human adipocytes in response to immunological stimuli and hypoxia. Horm Metab Res 41, 183-189.
74. Gregor MF & Hotamisligil GS (2007) Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 48, 1905-1914.
75. Madani R, Karastergiou K, Ogston N et al. (2009) Rantes release by human adipose tissue in vivo and evidence for depot specific differences. Am J Physiol Endocrinol Metab 296, E1262-E1268.
76. Herder C, Hauner H, Kempf K et al. (2007) Constitutive and regulated expression and secretion of interferon-gammainducible protein 10 (IP-10/CXCL10) in human adipocytes. Int J Obes (Lond) 31, 403-410.